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P450 oxidoreductase (POR) is the obligatory flavoprotein intermediate that transfers electrons from reduced ni-
cotinamide adenine dinucleotide phosphate (NADPH) to all microsomal cytochrome P450 enzymes. Although mouse
Por gene ablation causes embryonic lethality, POR missense mutations cause disordered steroidogenesis, ambiguous
genitalia, and Antley-Bixler syndrome (ABS), which has also been attributed to fibroblast growth factor receptor
2 (FGFR2) mutations. We sequenced the POR gene and FGFR2 exons 8 and 10 in 32 individuals with ABS and/
or hormonal findings that suggested POR deficiency. POR and FGFR2 mutations segregated completely. Fifteen
patients carried POR mutations on both alleles, 4 carried mutations on only one allele, 10 carried FGFR2 or
FGFR3 mutations, and 3 patients carried no mutations. The 34 affected POR alleles included 10 with A287P (all
from whites) and 7 with R457H (four Japanese, one African, two whites); 17 of the 34 alleles carried 16 “private”
mutations, including 9 missense and 7 frameshift mutations. These 11 missense mutations, plus 10 others found
in databases or reported elsewhere, were recreated by site-directed mutagenesis and were assessed by four assays:
reduction of cytochrome c, oxidation of NADPH, support of 17a-hydroxylase activity, and support of 17,20 lyase
using human P450c17. Assays that were based on cytochrome c, which is not a physiologic substrate for POR,
correlated poorly with clinical phenotype, but assays that were based on POR’s support of catalysis by P450c17—
the enzyme most closely associated with the hormonal phenotype—provided an excellent genotype/phenotype
correlation. Our large survey of patients with ABS shows that individuals with an ABS-like phenotype and normal
steroidogenesis have FGFR mutations, whereas those with ambiguous genitalia and disordered steroidogenesis
should be recognized as having a distinct new disease: POR deficiency.
Introduction
P450 oxidoreductase (POR) is the single flavoprotein
that transfers electrons from reduced nicotinamide ad-
enine dinucleotide phosphate (NADPH) to all micro-
somal (type 2) cytochrome P450 enzymes. The human
genome contains 57 genes for cytochrome P450 en-
zymes, of which 50 encode microsomal P450s, including
15 genes encoding hepatic drug-metabolizing P450s; 20
genes encoding P450s involved in the biosynthesis of
cholesterol, steroid hormones, fatty acids, and eicosa-
noids; and 15 genes encoding “orphan” P450 enzymes
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whose catalytic roles are unclear (Guengerich 2004). As
all of these microsomal enzymes require POR for ca-
talysis, one would predict that disruption of POR would
have devastating consequences. Not surprisingly, Por
knockout mice are embryonic lethal (Shen et al. 2002;
Otto et al. 2003), apparently due to disruption of ex-
trahepatic P450 enzymes, as liver-specific knockout of
Por yields phenotypically and reproductively normal
mice that accumulate hepatic lipids and have a remark-
ably diminished capacity for hepatic drug metabolism
(Gu et al. 2003; Henderson et al. 2003). Similarly, glob-
ally hypomorphic Por mice also have reduced hepatic
drug metabolism (Wu et al. 2005).
Despite the dire consequences in Por knockout mice,
we have recently identified five missense mutations and
a splicing mutation in the POR genes of four patients
who had hormonal evidence for partial, combined de-
ficiencies of two steroidogenic microsomal P450 en-
zymes: P450c17, which catalyzes steroid 17a-hydroxy-
lation and 17,20 lyase activity, and P450c21, which
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catalyzes steroid 21-hydroxylase activity (Flu¨ck et al.
2004). Combined deficiency of these enzymes was first
reported in 1985 (Peterson et al. 1985), and we had
suggested that mutation of POR might explain the hor-
monal phenotype (Miller 1986). However, the involve-
ment of POR with so many P450 enzymes, the lack of
a published POR gene sequence, and the severity of the
Por knockout mouse phenotype had dissuaded inves-
tigators from pursuing POR as a candidate gene (Mil-
ler 2004). Three of the four index cases also had the Ant-
ley-Bixler skeletal malformation syndrome (ABS [MIM
207401]), which is characterized by craniosynostosis,
radioulnar or radiohumeral synostosis, bowed femora,
and other bony deformities (Antley and Bixler 1975;
DeLozier et al. 1980; Hassell and Butler 1994; Crisponi
et al. 1997).
Work in the 1990s showed that four phenotypically
related craniosynostosis syndromes—Apert, Crouzon,
Jackson-Weiss, and Pfeiffer syndromes—were caused by
mutations in the gene for fibroblast growth factor re-
ceptor 2 (FGFR2) (Jabs et al. 1994; Muenke et al. 1994;
Reardon et al. 1994; Gorry et al. 1995; Park et al.
1995a, 1995b; Schell et al. 1995; Wilkie et al. 1995;
Meyers et al. 1996) and that the same FGFR2 missense
mutation, S351C, could be found in Crouzon and Pfeif-
fer syndromes (Pulleyn et al. 1996; Gripp et al. 1998;
Okajima et al. 1999), suggesting that each eponymic
syndrome is a phenotypic variant of a single genetic
disorder. The heterozygous gain-of-function mutation
C342Y is sufficient to cause craniosynostosis and skel-
etal abnormalities in knock-in mice (Eswarakumar et
al. 2004), consistent with the dominant inheritance of
these craniosynostosis syndromes. FGFR2 mutations
were also reported in patients with ABS without genital
ambiguity or other evidence of disordered steroidogen-
esis (Chun et al. 1998; Reardon et al. 2000). However,
FGFR2 mutations were not found in a series of patients
with ABS who had evidence of disordered steroidogen-
esis (Reardon et al. 2000), and FGFR1 and FGFR3
mutations were not found in a similar patient (Roth et
al. 2000). We (Flu¨ck et al. 2004)—and subsequently
others (Adachi et al. 2004; Arlt et al. 2004; Fukami et
al. 2005)—have found POR mutations in all examined
patients who had the ABS phenotype with evidence of
abnormal steroidogenesis, indicating that what has been
termed “ABS” is, in fact, two distinct disorders, as was
first suggested by Reardon and Winter (Reardon et al.
2000). Thus, ABS without disordered steroidogenesis is
a variant of the autosomal dominant group of cranio-
synostosis syndromes caused by mutant FGF receptors,
usually FGFR2, and ABS with disordered steroidogen-
esis is a novel autosomal recessive disorder caused by
mutations in POR.
We have now examined the POR genes in 32 addi-
tional patients, including 31 patients in whom ABS was
initially diagnosed, and in another 6 patients with the
Beare-Stevenson craniosynostosis syndrome, which can
be associated with genital anomalies. Fifteen of the 19
patients having abnormal genitalia and disordered ste-
roidogenesis were homozygotes or apparent compound
heterozygotes for POR mutations that destroyed or dra-
matically inhibited POR activity; only one mutant allele
was identified in the other 4 patients. Of the 12 patients
with normal genitalia and normal steroidogenesis diag-
nosed as having ABS, 9 carried FGFR2 or FGFR3 mu-
tations and none carried POR mutations on both alleles.
These data are consistent with the emerging view that
patients with ABS fall into two distinct groups that
should now be categorized as two distinct diseases (Miller
2004).
Subjects and Methods
Clinical Material
Samples 1–32 were from patients identified by various
medical geneticists as having ABS on the basis of dys-
morphic features or identified by pediatric endocrinol-
ogists as having combined 17a-hydroxylase and 21-
hydroxylase deficiencies. All samples were collected in
accordance with local institutional review board or med-
ical ethics committee guidelines. Not all clinical data are
available for all subjects. Exons 8 and 10 of FGFR2
were sequenced in all patients; only the FGFR sequenc-
ing in addition to exons 8 and 10 of FGFR2 is specif-
ically mentioned below. The available clinical histories
and hormonal data are summarized below, and the avail-
able dysmorphological data are summarized in table 1;
craniosynostosis and radioulnar or radiohumeral syno-
stosis were confirmed radiographically.
Patient 1 (IRL1), who has been described recently (Hur-
ley et al. 2004), was born at 38 wk, weighed 2.98 kg,
and had a head circumference of 31 cm, with midface
hypoplasia. He had fused lambdoid and sagittal sutures,
radiohumeral synostosis, and femoral bowing. He was
46,XY, with a stable 8;12 translocation that was also
seen in the father. The phallus was small, and the la-
bioscrotal folds were fused. At age 2 wk, the patient had
low serum cortisol (2.3 mg/dl), but it rose normally to
16.5 mg/dl after stimulation with adrenocorticotropic
hormone (ACTH [corticotropin]). ACTH was normal,
at 28 pg/ml. At age 2 wk, the patient had normal values
for androstenedione (1.2–2.5 nmol/L), dehydroepian-
drosterone sulfate (DHEAS) (0.1 mmol/L), and testos-
terone (1.8 nmol/L). Urinary steroids included decreased
amounts of C19 steroid sulfates and increased C21 ste-
roids. No mutations were found in exons 7 and 10 of
FGFR3, but the patient was heterozygous for the FGFR1
mutation I300T. This mutation has been reported in a
single case of trigonocephaly (Kress et al. 2000).
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Patient 2 (AUS2), a 46,XY male, was delivered at 37
wk by emergency cesarean section for abruptio placen-
ta. Height, weight, and head circumference were at the
50th percentile for gestational age. There was propto-
sis, brachycephaly, frontal and temporal bossing, and
ridging of the posterior sutures, but the metopic, sag-
ittal, and coronal sutures were open. There was limita-
tion of supination and elbow extension but no radiologi-
cally apparent synostosis. There also was camptodactyly,
arachnodactyly, rocker-bottom feet, choanal stenosis,
several hemivertebrae, bronchomalacia, and an absent
auditory meatus and absent ossicular chain on one side.
There was a horseshoe kidney, micropenis, hooded pre-
puce, hypospadias, chordee, bilaterally descended testes,
and anteriorly placed anus. At age 1 year, the patient
had normal cortisol (594 nmol/L), but ACTH was ele-
vated (137 pg/ml; normal [nl] !50 pg/ml). Progesterone
(143 nmol/L; nl !1.6 nmol/L) and 17-hydroxyprogester-
one (17OHP) (71.6 nmol/L; nl !3 nmol/L) were elevated
and were hyperresponsive to stimulation with ACTH,
whereas DHEA (0.31 nmol/L; nl 10.7 nmol/L) and an-
drostenedione (0.3 nmol/L; nl 10.4 nmol/L) were low
and were unresponsive to ACTH. Sequencing of exons
7, 8, and 10 of FGFR1, FGFR2, and FGFR3 was
normal.
Patient 3 (PL1), born at 38 wk with severe oligohy-
dramnios, had a large forehead, hypertelorism, abnor-
mal ears, conductive hearing loss, craniosynostosis re-
quiring ventriculoperitoneal shunting, radiohumero-
ulnar synostosis, and camptodactyly. He was 46,XY,
with micropenis, hypospadias, and bilateral cryptorchi-
dism. The 17OHP on newborn screening was 120 nmol/
L at age 3 d and 193 nmol/L at age 5 d (nl !10 nmol/
L) and was 3,780 mg/dl by radioimmunoassay at age 12
d (nl !200 mg/dl). These 17OHP data led to a presump-
tive diagnosis of congenital adrenal hyperplasia due to
21-hydroxylase deficiency (despite the genital findings),
but sequencing of the CYP21 gene was normal. The
patient was treated with replacement doses of gluco-
corticoids and mineralocorticoids but died of “septic
shock” at another hospital at age 3 years; no hormonal
evaluation was done at that time.
Patient 4 (CF1) was a 38-wk-old, 46,XY, SRY-positive
phenotypic female who weighed 2,055 g at birth. ABS
was diagnosed at birth on the basis of craniosynostosis,
radiohumeral synostosis with shortened humeri, midface
hypoplasia, a narrow thoracic cage with pectus exca-
vatum, and an absent corpus callosum (all confirmed by
radiographic studies). She had normal female external
genitalia; ultrasonography showed no uterus or ovaries,
small adrenals, and normal kidneys; and a radiographic
contrast study confirmed the presence of a blind vaginal
pouch. She had profound respiratory distress and fre-
quent apneic episodes and died at age 3 wk. A limited
hormonal evaluation included a Mu¨llerian inhibiting
substance of 34.9 pmol/L (normal for a female but in-
dicating Sertoli cell failure in a male); slightly elevated
aldosterone (126 ng/dl; nl !100 ng/dl); high 11-deoxy-
cortisol (6271 ng/dl; nl !150 ng/dl); and normal plasma
renin content (27 ng/L), ACTH (26 pg/ml), cortisol (205
nmol/L), 17OHP (1.4 nmol/L), DHEA (25 nmol/L),
DHEAS (8.9 mmol/L), and androstenedione (5.4 nmol/
L). The mother also had two spontaneous abortions, and
a maternal uncle died soon after birth with ambiguous
genitalia, but no hormonal testing was done, and no
samples are available for DNA sequencing.
Patient 5 (337) was a phenotypically female infant with
cloverleaf skull, craniosynostosis, bowed femora, radio-
humeral synostosis, and arachnodactyly, who also had an
imperforate anus, clitoromegaly, hypoplastic labia ma-
jora, and fused labia minora; a karyotype was not done.
Although these findings suggest hyperandrogenism, no
hormonal studies were done. She died at age 4 years from
pneumonia, complicated by severe kyphoscoliosis. Se-
quencing of all FGFR2 exons was normal.
Patient 6 (259), a boy born to parents from Senegal,
had craniosynostosis, cloverleaf skull, radiohumeral syno-
stosis, bowed femora, arachnodactyly, and micropenis.
No hormonal data are available. He is now 9 years old
and has severe kyphoscoliosis. Sequencing of all FGFR2
exons was normal.
Patient 7 (699) was the product of a therapeutic abor-
tion performed at 22 wk gestation because of ultrasono-
graphic detection of craniosynostosis, bilateral radiohu-
meral synostosis, bowing of long bones, and arach-
nodactyly. Karyotype was 46,XY, and the external gen-
italia were normal. Amniotic fluid steroids were not
measured, but, because of the suspicion of ABS, gas
chromatographic analysis of liver tissue was performed
and showed “substantially increased” lanosterol and
dihydrolanosterol.
Patient 8 (JPSZ) had craniosynostosis, bowed femora,
elbow synostosis, Arnold-Chiari malformation, scrotal
hypoplasia, and a “small” penis. No steroids were mea-
sured other than normal total serum cholesterol.
Patients 9 (JPSS) and 10 (JPSB) were siblings. Both
had craniosynostosis and elbow synostosis. Patient 9
had bowed femurs and fractures; this information is not
known for patient 10. Patient 9 was said to have an
undescribed genital anomaly, and patient 10 had un-
descended testes. No other data are available.
Patient 11 (MC25), who has been described elsewhere
(Hassell and Butler 1994), was small for gestational age
and had brachycephaly, midface hypoplasia, proptosis,
radiohumeral synostosis, bowed femora, and choanal
atresia or stenosis. She was 46,XX, with clitoromegaly,
no vaginal orifice, and a vesicovaginal fistula. No hor-
monal data are available.
Patients 12–23 were described elsewhere (Reardon et
al. 2000) (see table 1). Patients 17, 18, and 22 were
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Table 2
Oligonucleotide Primers for PCR, Sequencing, and
Site-Directed Mutagenesis
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
46,XY; the others were 46,XX. Patient 12 was originally
described by DeLozier et al. (1980); genital anoma-
lies were not described. At age 18 years, patient 12 had
normal excretion of urinary free cortisol (67 mg/24 h),
17-hydroxycorticosteriods (7.5 mg/24 h), and 17-keto-
steroids (8.5 mg/24 h). Patient 13 had low excretion of
free cortisol (3.7 mg/24 h), 17-hydroxycorticosteroids
(0.2 mg/24 h), and 17-ketosteroids (1.9 mg/24 h). Pa-
tient 16, illustrated in figure 1 of Reardon et al. (2000),
had genital ambiguity (clitoromegaly and hooded pre-
puce), fused labia, elevated 17OHP (42.8 nmol/L; nl
!12 nmol/L), and a cortisol of 220 nmol/L (nl 80–800),
which rose to 534 nmol/L in response to ACTH. Patient
20, initially described by Kumar and Masel (1997), re-
portedly had an “abnormal steroid profile,” which was
not described further, and had a urogenital sinus, ves-
tigial uterus, and a posteriorly placed septated vagina.
For patient 22, gas chromatographic analysis of urinary
steroids at age 18 mo showed elevated excretion of 11b-
hydroxyandrosterone plus 17-hydroxypregnanolone (80
mg; nl !50 mg), pregnanetriol (60 mg; nl !50 mg), tetra-
hydrocortisone (320 mg; nl 50–250 mg), allotetrahydro-
cortisol (380 mg; nl 20–300 mg), a-cortolone (380 mg; nl
!50 mg), a-cortol (120 mg; nl !20 mg), and b-cortolone
plus b-cortol (80 mg; nl !50 mg).
Patient 24 (56661) had craniosynostosis with clover-
leaf skull, brachycephaly, midface hypoplasia, elbow
synostosis, bilateral choanal atresia, proptosis, femoral
fractures, and only 11 pairs of ribs. The corpus callosum
was “small,” and the cerebral gyri were “abnormal.” A
randomly obtained cortisol in infancy was 3.9 mg/dl, but
an ACTH test was not done; hence, this value is not
informative.
Patients 25–30 initially had a clinical diagnosis of
ABS, which has been reconsidered in some cases. None
of these patients had genital malformations or known
disorders of steroidogenesis. Patient 25 (JPAS), a 46,XY
male with unilateral agenesis of one adrenal, kidney,
ureter, testis, and spermatic cord, had a classic ABS phe-
notype (table 1), but sequencing of all exons of FGFR2
was normal. Gas chromatographic analysis of urinary
steroids at age 4 years showed normal 24-h excretions
of tetrahydrocortisone (690 mg), tetrahydrocortisol (240
mg), allotetrahydrocortisol (180 mg), a-cortolone (260
mg), a-cortol (110 mg), and b-cortolone plus b-cortol
(240 mg). Patient 26 (1110) had a family history of un-
specified renal disease. Patients 28 (1323) and 29 (1434),
reported as cases 1 and 2 by Okajima et al. (1999), are
both heterozygous for FGFR2 mutation S351C. Patient
28 had a 2.5-cm phallus, contractures of the elbows and
knees without synostosis and Peters anomaly, and was
subsequently considered to have Pfeiffer syndrome. Pa-
tient 29 had radioulnar—but not radiohumeral—syno-
stosis, knee contractures without synostosis and Pe-
ters anomaly, and was subsequently considered to have
Crouzon syndrome. Patient 30 (2430) developed acan-
thosis nigricans 4–5 years after the initial diagnosis of
ABS and was then considered to have Crouzonodermo-
skeletal syndrome; the patient was found to be hetero-
zygous for FGFR3 mutation A391E.
Patient 31 (STJ1), a 46,XY male identified as having
ABS at birth, had craniosynostosis, brachycephaly,
radioulnar synostosis, femoral bowing, midface hypo-
plasia, and bilateral choanal stenosis. There was no gen-
ital ambiguity, but the patient had microphallus and
bilaterally descended testes. At age 9 mo, an afternoon
17OHP was 360 nmol/L (nl !2 nmol/L at this age), but
8 A.M. values for cortisol (371 nmol/L), androstenedione
(1.7 nmol/L), DHEAS (0.33 mmol/L), testosterone (!0.17
nmol/L), and aldosterone (2.8 nmol/L) were all normal
for the patient’s age. The elevated 17OHP in the pres-
ence of normally low C19 steroids suggested combined
partial deficiencies of P450c17 and P450c21. At age 32
mo, the 17OHP remained greatly elevated (72.6 nmol/
L).
Patient 32 (ISRL1), who has been described elsewhere
(Augarten et al. 1992), was the 46,XY, 2,620-g, 48-cm
product of a 38-wk pregnancy; the patient had no dys-
morphic features suggestive of ABS but had a 1-cm mi-
crophallus, a bifid scrotum, glandular hypospadias, and
bilaterally palpable testes. He had some limitation of el-
bow extension attributed to arthrogryposis; X-rays of the
elbow joints were not done. Hormonal stimulation of the
adrenal with ACTH and of the testes with human cho-
rionic gonadotropin showed a pattern consistent with
partial deficiencies of the activities of both P450c17 and
P450c21 (Augarten et al. 1992). He entered puberty spon-
taneously but had hypergonadotropic hypogonadism
and required ongoing supplementation with testoster-
one. He is now 22 years old and has required no glu-
cocorticoid, mineralocorticoid, or salt supplementation.
Patients 33–38 had Beare-Stevenson syndrome, which
can result in skeletal and genital anomalies (Przylepa et
al. 1996). Patients 33, 36, and 37 had rugated labia
majora; patient 36 had hypoplastic labia majora. Pa-
tients 35, 36, 37, and 38 had anteriorly placed anus. No
endocrine data are available for these patients.
PCR and Sequencing
Specific primers in the intronic regions flanking the
15 exons of POR were designed on the basis of National
Center for Biotechnology Information (NCBI) sequences
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Table 3
Primers for PCR and Sequencing, and Product Sizes
of POR Amplicons
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
GI 4508114 and GI 11181841 (see table 2). These prim-
ers amplified each exon with at least 100 bases of flank-
ing intronic DNA; the sizes of the PCR products are
listed in table 3. Genomic DNA samples (10 ng) were
used as templates for PCR amplification in a 5-ml or 10-
ml reaction. PCR amplification of exons 1, 2, 3, 5, 7,
and 8–9 was performed using AmpliTaq Gold (Applied
Biosystems) under high touchdown cycling conditions,
starting at 95C for 5 min, followed by 14 touchdown
cycles of 94C for 20 s, 65C–58.5C for 20 s (the an-
nealing temperature for each subsequent cycle was de-
creased by 0.5C), and 72C for 1 min. This was fol-
lowed by 35 cycles of PCR amplification at 94C for 20
s, at 58C for 20 s, and at 72C for 1 min; the final
extension was held at 72C for 10 min, followed by 4C
to stop the reaction. PCR amplification of exons 3, 6,
and 10–11 was performed using Platinum Taq (Invitro-
gen), and amplification of exons 12–15 was performed
using Platinum Taq with N,N,N-trimethylglycine (be-
tain) (Invitrogen) at 95C for 1 min, followed by 14
touchdown cycles, 35 cycles of PCR amplification, and
a 10-min final extension at 72C, as described above.
When updated databases revealed SNPs in the sites rec-
ognized by some primers, additional primers were de-
signed (see table 2) and used as described for exons 12–
15. FGFR2 exons 8 and 10 were sequenced as described
elsewhere (Meyers et al. 1996), and FGFR2 exon 11
was sequenced in the patients with Beare-Stevenson syn-
drome, as described by Przylepa et al. (1996). The PCR
products were subjected to automated direct sequencing
with the use of the primers listed in table 2. All cycling
for PCR and sequencing was performed on ABI Gene-
Amp PCR System 9700 thermocyclers. The sequencing
was performed with ABI BigDye terminator, version 3.1,
and was displayed on ABI 3730#1 DNA Analyzer. Ge-
nomic DNA from four normal males and four normal
females was used as a reference. Mutations were ana-
lyzed with Mutation Surveyor 2.02 (see the Softgenetics
Web site). All identified mutations were confirmed by
forward and reverse sequencing. Nucleotide mutations
are numbered in accordance with the NCBI reference
sequence NM_000941.1, and protein sequence muta-
tions are numbered in accordance with the NCBI ref-
erence sequence NP_000932.1.
Sequence Analysis and Molecular Modeling of Human
POR
The POR sequences from human, rat, Xenopus, Dro-
sophila, and yeast were aligned with ClustalW (Thomp-
son et al. 1994), and sequences were displayed and ed-
ited using GeneDoc. Molecular modeling of human POR
was performed by MODELLER (Sali and Blundell 1993;
Fiser et al. 2000), which uses satisfaction of spatial re-
straints for comparative modeling of proteins. The mod-
el was based on the X-ray crystal structure of rat POR
(Wang et al. 1997), which shares 94% sequence identi-
ty with human POR. Energy minimizations were per-
formed with GROMOS96 (see the GROMOS Home
Page), and the model was examined and edited using
DeepView (Guex and Peitsch 1997) and POVRAY (see
the Persistence of Vision Raytracer Web site).
Expression of Wild-Type and Mutant POR in Bacteria
Human POR cDNA lacking codons for 27 N-terminal
residues (Dierks et al. 1998) was subcloned into pET22b
for bacterial expression. Mutant cDNA expression vec-
tors were generated by PCR-based, site-directed muta-
genesis with the use of the primers shown in table 2.
The resulting mutated plasmids were selected by diges-
tion with DpnI and were propagated in Escherichia coli
DH5a. All POR mutations were confirmed by direct
sequencing.
E. coli BL21DE3(pLysS) transformed with pET22b
were grown in terrific broth (Dierks et al. 1998) sup-
plemented with 40 mM FeCl3, 4 mM ZnCl2, 2 mM CoCl2,
2 mM Na2MoO4, 2 mM CaCl2, 2 mM CuCl2, 2 mM
H3BO3, 10% (v/v) potassium phosphate solution (0.17
M KH2PO4, 0.72 M K2HPO4 pH 7.4), 0.5 mg/ml ri-
boflavin, 50 mg/ml ampicillin, and 34 mg/ml chloram-
phenicol at room temperature to an optical density (OD)
600 nm of 0.4 and were induced with 0.4 mM isopropyl-
1-thio-b-D-galactopyranoside (IPTG) overnight. The
bacteria were washed with PBS and were resuspended
in 100 mM Tris-acetate (pH 7.6), 0.5 M sucrose, and 1
mM EDTA. The bacteria were treated with lysozyme
(0.5 mg/ml) and EDTA (0.1 mM [pH 8.0]) to generate
spheroplasts. The spheroplasts were pelleted by centrif-
ugation (5,000 # g for 15 min); were resuspended in
100 mM potassium phosphate (pH 7.6), 6 mM MgOAc,
0.1 mM DTT, 20% (v/v) glycerol, 0.2 mM PMSF, and
0.1 mM DNase I; and were disrupted by sonication (30-
s on/off cycles for 15 min at 40% power). The lysate
was cleared of cellular debris by centrifugation at
12,000 # g for 5 min, and then the membranes in the
supernatant were pelleted at 150,000 # g for 45 min
at 4C. Membranes were resuspended in 50 mM Tris-
HCl (pH 8.0), 1 mM EDTA, and 20% (v/v) glycerol;
were stored at 70C; and were used as a source of
POR.
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Figure 1 Purification of POR and cytochrome b5. Left panel,
10% SDS-polyacrylamide gel showing purified preparations of wild-
type POR used for quantitation and normalization of POR mutants;
right panel, 12% SDS-polyacrylamide gel showing purified cytochrome
b5 used in assays of the 17,20 lyase reaction. Both gels were purposely
overloaded to permit identification of trace contamination. The gels
were stained with Coomassie Brilliant Blue.
Purification and Quantitation of Wild-Type and Mutant
POR
Bacterial membranes containing POR were solubilized
by stirring for 2 h at 4C in 20 mM potassium phosphate
(pH 7.6) containing 20% glycerol, 0.1 mM EDTA, 1
mM PMSF, 1 mg/L pepstatin, 10 mg/L leupeptin, 0.2%
sodium cholate, and 0.2% Triton X-100 (Calbiochem).
Insoluble material was removed by centrifugation at
100,000 # g for 1 h, and the supernatant was loaded
on a 2′,5′-ADP-Sepharose column (Sigma) equilibrated
with 20 mM potassium phosphate (pH 7.6) containing
20% glycerol, 0.1 mM EDTA, and 0.2% sodium cho-
late. The column was first washed with 5 vol of this
buffer; then with 5 vol of 100 mM potassium phosphate
(pH 7.6) containing 20% glycerol, 0.1 mM EDTA, 0.2%
sodium cholate, and 250 mM sodium chloride; and fi-
nally with 5 vol of 20 mM potassium phosphate (pH
7.6) containing 20% glycerol, 0.1 mM EDTA, 0.2%
sodium cholate, and 2 mM adenosine. POR was eluted
with 20 mM potassium phosphate (pH 7.6) containing
20% glycerol, 0.1 mM EDTA, 0.2% sodium cholate,
and 5 mM 2′-AMP. The cholate and 2′-AMP were re-
moved from POR preparations by dialysis against 20
mM potassium phosphate (pH 7.6) containing 10%
glycerol.
The mutant POR proteins were quantitated by west-
ern blotting by comparison with a standard curve of
purified wild-type POR protein. Wild-type POR protein
was quantitated by Bradford assay, and the purity of the
POR preparation was confirmed by SDS-PAGE (fig. 1).
The standard curve, using different amounts of wild-
type POR protein, and the membrane preparations from
bacteria expressing various POR mutants were sepa-
rated by SDS-PAGE, transferred on polyvinyldifluoride
(PVDF) membranes, and probed with a rabbit polyclo-
nal antibody against wild-type human POR (Stressgen)
at a dilution of 1:1,000. The blot was developed with
a chemiluminescence-based detection reagent (Pierce)
by employing goat anti-rabbit antibody, coupled with
horseradish peroxidase. Signals were detected on a
STORM 860 phosphorimager, operating in blue fluo-
rescence mode, and were quantitated with ImageQuant
software. All POR levels were normalized against wild-
type POR.
Expression of Human P450c17 in Yeast
Yeast strain W(B), which lacks the endogenous yeast
Cpr1 gene (Pompon et al. 1995), was propagated and
transiently transfected with pYeSF2 expressing human
P450c17, as described (Auchus et al. 1998). Yeast mi-
crosomes were prepared as described (Auchus et al.
1998), microsomal proteins were quantitated colori-
metrically (protein Assay Dye Reagent [Bio-Rad]), and
P450 content was measured spectroscopically (Omura
and Sato 1964).
POR Assays Based on Cytochrome c
The ability of bacterially expressed POR to reduce
cytochrome c or to oxidize NADPH was measured, using
a method based on that of Lu et al. (1969), by quan-
titating the change in A550 when oxidized cytochrome
c is reduced (extinction coefficient of 21.1 mM1)
(Van and Slater 1962). The assay system contained an
NADPH regeneration system, consisting of 0.1M Tris-
HCl (pH 7.8), 2 mM glucose-6-phoshate (Sigma), and
3 U glucose-6-phosphate dehydrogenase (Sigma) in a 1-
ml volume. The cytochrome c concentration was 40
mM when NADPH was the variable substrate, and the
NADPH concentration was 5 mM when cytochrome c
was the variable substrate. Assays were performed with
15–20 mg of bacterial membranes containing 5 pmol of
POR, as assessed in comparison to bacterially expressed
wild-type POR, as described above. A550 was moni-
tored against time, and velocities were expressed as
(nmol reduced cytochrome c) 7 (nmol POR)1 7 (min1).
Data were analyzed using LEONORA (Cornish-Bowden
1995) (see the Centre National de la Recherche Scien-
tifique Marseilles Group in Enzyme Kinetics and Control
Analysis Web site).
POR Assays Based on P450c17
The various POR missense mutants all expressed at
similar levels. The ability of bacterially expressed POR
to support 17a-hydroxylase and 17,20 lyase activities
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of P450c17 was then assayed using human P450c17 ex-
pressed in yeast. Yeast membrane fractions containing
10 pmol of P450c17 were combined with bacterial mem-
branes containing 20 pmol POR by emulsifying with 20
mg phosphatidylcholine in 100 mM potassium phos-
phate, 6 mM potassium acetate, 10 mM MgCl2, 1 mM
reduced glutathione, 20% glycerol, 3 U glucose-6-phos-
phate dehydrogenase, 0.1 mM glucose-6-phosphate, and
radiolabeled substrate for 20 min at 25C in a total
volume of 200 ml. For the 17a-hydroxylase reaction, the
substrate was 14C progesterone; for the 17,20 lyase re-
action, the substrate was 3H 17a-hydroxypregnenolone
(17OH Preg), with 50 pmol cytochrome b5 (added to
facilitate the lyase reaction allosterically) (Auchus et al.
1998). The reactions were started by adding 20 ml 10
mM NADPH; reactions were incubated at 37C for var-
ious lengths of time and were stopped by adding ethyl
acetate:iso-octane (3:1) to extract the steroids. Steroids
from different reactions were spotted on silica gel 60 F-
254 thin-layer chromatography (TLC) plates (Merck)
and were developed with ethyl acetate:chloroform (3:
1) (Lin et al. 1991). Steroids were quantified by phos-
phorimaging for P450c17/POR assays, and kinetic be-
havior was approximated as a Michaelis-Menten sys-
tem. Curve fitting and calculations of maximum velocity
(Vmax) and apparent Michaelis constant (Km) values were
performed using LEONORA (Cornish-Bowden 1995).
Expression and Purification of Cytochrome b5
For use in the 17,20 lyase assays, human cytochrome
b5 was prepared in E. coli strain BL21(DE3) transformed
with plasmid pLW01b5 containing human cytochrome
b5 cDNA and was selected over several cycles, as de-
scribed (Miroux and Walker 1996). A single colony of
transformed E. coli was inoculated into Luria-Bertani
(LB) medium containing 100 mg/ml carbenicillin, grown
to an OD 600 nm of 0.5–0.7, and IPTG was added to
a final concentration of 0.4 mM. Cell density was mea-
sured every 30 min; when the OD 600 nm started to
rise again (90–180 min after induction), 100 ml of cells
diluted at a ratio of 1:50 were plated on LB agar plates
containing 100 mg/ml carbenicillin and 0.4 mM IPTG
and were allowed to grow overnight at 37C. A single
colony was grown the next day, and the process of in-
duction and selection with carbenicillin and IPTG was
repeated three more times. After four cycles of selection,
the E. coli were transformed with plasmid pLysS/RARE,
which encodes lysozyme and six rare tRNAs that assist
the expression of mammalian proteins by complement-
ing the codon bias of E. coli. The resultant E. coli
A11(DE3) pLysS/RARE cells were used for expression
of cytochrome b5. Expression and purification was per-
formed as described (Mulrooney and Waskell 2000), and
purity was assessed by SDS-PAGE (fig. 1).
Results
Anatomic Phenotype
A summary of the dysmorphologic features in our
patients is presented in table 1. The most consistent fea-
tures were radiographically demonstrated craniosyno-
stosis, either radioulnar or radiohumeral synostosis, and
femoral bowing. Other features generally associated
with ABS (brachycephaly, femoral fractures, midface
hypoplasia, proptosis choanal atresia, arachnodactyly,
camptodactyly, and rocker-bottom feet) were also re-
ported in several patients, and some patients also had
conductive hearing loss. A comparison of these clinical
findings and the mutation analyses (table 4) shows that,
aside from the genital anomalies attributable to disor-
dered steroidogenesis, no morphologic feature distin-
guished patients with POR mutations from those with
FGFR mutations.
Hormonal Phenotype
Clear hormonal and genital data are not available for
all patients, since most were not seen by a pediatric
endocrinologist. Where data are available, a pattern
emerges that closely resembles the pattern originally de-
scribed by Peterson et al. (1985), as well as that described
in our previous study (Flu¨ck et al. 2004). In all patients
in whom it was measured, 17OHP was markedly el-
evated and was hyperresponsive to stimulation with
ACTH, as is typical of defects in steroid 21-hydroxylase
(P450c21) (Miller 1994). Basal values for cortisol and
other steroids tended to be normal, but such values are
not truly informative in the absence of stimulation with
ACTH. Despite the elevated values for 17OHP, values
for C19 steroids were normal or low, indicating a rel-
atively greater deficiency in the 17,20 lyase activity of
P450c17 (Geller et al. 1997). There was no clear evi-
dence of any patient suffering a life-threatening adrenal
crisis from glucocorticoid and mineralocorticoid defi-
ciency, but there also was no hormonal evaluation of
the several individuals who died in childhood. The pos-
sibility of life-threatening adrenal insufficiency remains
a concern.
DNA Sequencing
Exons 8 and 10 of FGFR2 are the most frequent sites
of mutation in the various craniosynostosis syndromes;
these exons were sequenced in all patients. In patients
5, 6, and 26, all exons of FGFR2 were sequenced. Ex-
cluding patients 33–38 with Beare-Stevenson syndrome,
FGFR2 mutation S351C was found in five patients,
other FGFR2 mutations (C342S, C342R, and P276V)
were found in three other patients, and one patient car-
ried the FGFR3 mutation A391E (table 4). None of these
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Table 4
Summary of Genetic Findings
PATIENT
NO.
PATIENT
ID
MUTATION (PARENTAL ETHNICITY) AT ALLELE
FGFR2
(EXONS 8 AND 10)1 2
1 IRL1 G539R (Irish) Frame 1 (white) FGFR1 I300T
2 AUS2 F646del (Laotian) A287P (white) nl
3 PL1 A287P (white) Frame 2 (Moroccan) nl (all FGFR2)
4 CF1 M263V (white) Not found (white) nl
5 337 A287P (French) Not found (French) nl (all FGFR2)
6 259 R457H (Senegalese) Not found (Senegalese) nl (all FGFR2)
7 699 Q153R (Algerian) Q153R (Algerian) nl
8 JPSZ R457H (Japanese) R457H (Japanese) nl
9 JPSS R457H (Japanese) Y459H (Japanese) nl
10 JPSB R457H (Japanese) Y459H (Japanese) nl
11 MC25 A287P (white) Frame 3 (Hispanic) nl
12 09742 A287P (white) A287P (white) nl
13 50081 A287P (white) Frame 4 (white) nl
14 11314 None found (British) None found (British) FGFR2 C342S
15 14506 None found (British) None found (British) FGFR2 S351C
16 14683 A287P (British) None found (British) nl
17 15441 None found (Pakistani) None found (Pakistani) FGFR2 C342R
18 16666 None found (white) None found (white) FGFR2 S351C
19 20554 None found None found FGFR2 S351C
20 24019 R457H (British) Frame 6 (British) nl
21 07862 None found (British) None found (British) nl
22 24872 A287P (British) Frame 7 (British) nl
23 14837 None found (Hispanic) None found (Hispanic) FGFR2 F276V
24 56661 A287P (white) R616X (white) nl
25 JPAS None found (Japanese) None found (Japanese) All FGFR2 nl
26 1110 None found (Arab) None found nl
27 1115 None found (white) None found (white) nl
28 1323 None found (Black) None found (Black) FGFR2 S351C
29 1434 None found (Black) None found (Black) FGFR2 S351C
30 2430 None found (Hispanic) None found FGFR3 A391E
31 STJ1 L565P (white) R457H (white) nl
32 ISRL1 T142A (Iraqi) Frame 5 (Yemeni) nl
33 MC15 None found (white) None found (white) FGFR2 Y375C
34 1095 None found (Hispanic) None found nl
35 1603 None found (Vietnamese) None found (Vietnamese) FGFR2 S372C
36 1771 None found (black) None found (black) FGFR2 Y375C
37 2353 A115V (white) None found FGFR2 Y375C
38 1156 None found None found nl
NOTE.—Frameshift mutations (base numbers refer to the ORF, with A of the first ATG as base
1): frame 1, 580-581insTACGTGGACAAGC; frame 2, 1551-1552ins TGCCCATGTTCGTGCGC;
frame 3, 1619-1620insCCTTCAAGGCCACCACGCCTGTCATCATGATGGGCCCCGGCACCGG-
GGT; frame 4, 1621-1622insC; frame 5, 1348-1349ins GAGC; frame 6, IVS6-2ArT; and frame 7,
IVS7(2-3)insT.
individuals with FGFR2 or FGFR3 mutations carried a
mutation in POR. Patient 1 carried the FGFR1 mutation
I300T and was also a compound heterozygote for two
POR mutations.
For the POR gene, all 15 exons and at least 50 bases
of each intron lying adjacent to the exons were se-
quenced on both strands in all samples. Additional prim-
ers were used at primer sites where the University of
California Santa Cruz (UCSC) Genome Browser iden-
tified polymorphisms. Allele assignments of identified mu-
tations were made by sequencing parental DNA when
such samples were available. SNPs permitted the iden-
tification of two alleles in most cases; however, we can
not rule out hemizygosity in patients 4–8 and 12 (table
4). The sequencing results are shown in figure 2, and
the allele assignments and the available data on ethnic
origins are summarized in table 4. The numbering of the
nucleotides is based on the NCBI human POR cDNA
sequence NM_000941.1; the ORF with A of the first
ATG is base 1. The corresponding amino acid numbers
in the protein are based on the NCBI POR protein ref-
erence sequence NP_000932.1. These sequences corre-
spond to the full-length, 680-aa human POR sequence.
Some other investigators (Adachi et al. 2004; Arlt et al.
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Figure 2 Sequences of POR mutations. The mutants shown are from the patients in the present study who had disordered steroidogenesis.
Each mutant is shown as a heterozygote in association with a wild-type allele, except for Q153R, which was only seen in a homozygously
affected patient. The mutated nucleotides, indicated by arrows, are 424ArG, causing T142A; 458ArG, causing Q153R; 787ArG, causing
M263V; 859GrC, causing A287P; 1370GrA, causing R457H; 1375TrC, causing Y459H; 1615GrA, causing G539R; 1694TrC, causing
L565P; 1845CrT, causing R616X; and 1937-1939delTCT, causing F646del. The location of each mutation is shown on a linear diagram of
the POR protein, as described by Wang et al. (1997), which illustrates the crystallographically inferred boundaries of the functional domains
of POR.
2004) have used NCBI sequence P16435, which is de-
rived from the SwissProt database and indicates that
human POR contains 677 residues (as does rat POR),
but the older SwissProt database misses the Met-Ile-Asn
sequence that precedes the Met in position 4 (correspon-
ding to rat position 1).
POR mutations were found in 19 of the 32 patients
with ABS (patients 33–38 are excluded because they had
Beare-Stevenson syndrome). Mutations were found on
only one allele in four samples (patients 4, 5, 6, and 16).
The other 15 patients carrying POR mutations included
3 in whom the mutation was homozygous, 4 proven
compound heterozygotes in whom allele assignments
were made by sequencing parental DNA, and 8 probable
compound heterozygotes in whom two heterozygous
mutations were found but allele assignments could not
be done because parental samples were not available.
The 34 affected alleles included 5 unique frameshift mu-
tations, 2 splice-site mutations, 26 missense mutations,
and 1 premature stop codon near the carboxyl-terminus
of the encoded POR protein. The five frameshift muta-
tions (“Frames 1–5” in table 4) grossly disrupted the fla-
vin mononucleotide (FMN)- and NADPH-binding sites
of POR, and four of them (Frames 1, 2, 4, and 5) also
caused premature stop codons upstream from residue
616, where the spontaneously occurring nonsense mu-
tation R616X was devoid of activity (described below).
The two intronic mutations, termed “Frame 6” and
“Frame 7” (table 4), disrupted the canonical splice-ac-
ceptor or -donor sites; the splice-site recognition programs
FSPLICE (see the Softberry Web site) and NNSplice (see
the Berkeley Drosophila Genome Project Web site) in-
dicate that each is very likely to disrupt splicing. Thus,
the mutations termed “Frames 1–7” were not tested in
vitro. Most missense mutations were found once, but
A287P was found on 10 alleles, and R457H was found
on 7 alleles. Thus, these two missense mutations ac-
counted for 17 of 34 (50%) of the identified POR mis-
sense mutations.
A287P and R457H Mutations
The A287P mutation was found only in samples from
subjects described as “white,” “Caucasian,” or “Euro-
pean.” This same mutation was also found on two of
eight alleles in our initial study (Flu¨ck et al. 2004) and
on one of four alleles in a subsequent study (Arlt et al.
2004), all in individuals of European heritage. Thus,
A287P is a frequent mutation causing POR deficiency
in this group. The nucleotide change 859GrC, which
is responsible for all identified cases of A287P, lies in
exon 8, changing the sequence from f(N)12GCTGC to
(N)12CCTGC, destroying the site recognized by restric-
tion endonuclease BbvI. We amplified exons 8 and 9 in
a single PCR using primers OR-8-9F and OR-8-9R (ta-
ble 3), yielding a product of 613 bp. Digestion of this
PCR product with BbvI yields four fragments of 250
bp, 167 bp, 101 bp, and 95 bp in the wild type but
yields only three fragments of 262 bp, 250 bp, and 101
bp in the mutant.
The R457H mutation was found in four of eight al-
leles from Japanese patients. This mutation destroyed
BsaXI and TstI sites, but these enzymes recognize de-
generate 33–37 base sequences and cut both strands
twice; hence, this approach did not yield a reliable di-
agnostic tactic. R457H was also found on 1 of 2 Jap-
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anese alleles in our initial study (Flu¨ck et al. 2004) and
on 2 of 4 alleles (Adachi et al. 2004) and 10 of 16 alleles
(Fukami et al. 2005) in two recent studies of Japanese
patients. However, other ethnic groups may also carry
the R457H mutation. The samples from patient 6, whose
parents are from Senegal; patient 21, from the United
Kingdom; and patient 31, whose parents are both French
Canadian, were heterozygous for the same 1370GrA
mutation causing the R457H missense mutation. In ad-
dition, Arlt et al. (2004) found R457H in a Polish pa-
tient. Thus, R457H is strongly—but not uniquely—as-
sociated with patients of Japanese heritage.
Mutations and Polymorphisms
Our previous study described the enzymology of the
five missense mutations (A287P, R457H, V492E, C569Y,
and V608F) identified in our initial four patients (Flu¨ck
et al. 2004). The present series adds the mutants or poly-
morphisms A115V, T142A, Q153R, M263V, Y459H,
A503V, G539R, L565P, R616X, V631I, and F646del. In
addition, we found the mutants or polymorphisms P228L,
R316W, G413S, and G504R by searching a publicly
available sequence database (see the BioVentures Web
site), and the missense mutation Y181D was reported in
another study (Arlt et al. 2004) but was not characterized
in a P450 assay. The incidences of these alleles and their
ethnic distributions are not yet available in the NCBI,
HapMap (see the International HapMap Project Web
site), or UCSC Genome Browser databases, although
these are being updated regularly. As discussed below, the
changes that were found in the patients disrupted ste-
roidogenesis and hence appear to be mutations, whereas
the changes that were found in databases had lesser (but
variable) effects and hence appear to be polymorphisms.
In the discussion of the enzymology below, all of these
amino acid changes are referred to as “mutations.”
Enzymology of the Amino Acid Replacement
Mutations
To understand the enzymatic consequences of each
amino acid replacement mutation, we built a computer
graphic model of the human POR that was based on
the crystallographically determined structure of rat POR,
which is 94% identical to human POR (Wang et al.
1997). The model of human POR was energetically fa-
vorable (total free energy was 33,952 kJ/mol for the
human POR model, compared with27,850 kJ/mol for
the rat POR structure) and closely resembled the rat
POR structure, as expected (fig. 3). In general, the mis-
sense mutations found in patients with ABS mapped to
functionally important domains of POR, and the ap-
parent polymorphisms mapped to less crucial regions.
Therefore, to assess the enzymatic consequences of each
missense mutant, we built bacterial expression vectors
for each and characterized their activities in four assays.
From the time of the initial identification and isolation
of POR (Lu et al. 1969), the standard POR assay has
been the reduction of cytochrome c, which is easily as-
sayed as change in absorption at 550 nm. To perform this
assay and also to measure NADPH oxidation, we ex-
pressed human POR mutants in bacteria in a form lacking
27 amino-terminal residues (N-27 POR) (Dierks et al.
1998), which is similar to N-24 rat POR, as human POR
has a 3-aa amino-terminal extension, compared with
rodent POR (NCBI accession numbers NC_000007,
NM_000941.1, and NP_000932.1). This form of POR
remains associated with membranes, as does wild-type
POR, and it is distinct from the soluble N-49 POR used
by Arlt et al. (2004). Table 5 shows the Km, Vmax, and
Vmax/Km (an estimate of catalytic efficiency) for the ca-
pacity of the wild type and the 21 missense mutants of
POR to catalyze the reduction of cytochrome c and the
oxidation of NADPH. We have previously measured these
variables for wild-type POR and for the A287P, R457H,
V492E, C569Y, and V608F mutants (Flu¨ck et al. 2004);
in each case, the values in table 5 are within 20% of the
previously measured values. An examination of the Vmax/
Km values, shown as percentages of the wild-type values,
reveals that there is a very broad range of enzymatic im-
pairment and that there is generally good agreement be-
tween the two assays. P228L, R316W, G413S, A503V,
and G504R, which were polymorphisms identified from
databases, retained 47%–100% of wild-type activity in
both assays, but the apparent polymorphism A115V,
found in a patient with Beare-Stevenson syndrome with
an FGFR2 mutation, had 41%–63% of wild-type activity
in the cytochrome c assays (but 70%–80% of wild-type
activity in P450c17 assays [table 6]); M263V and V631I,
found as heterozygotes during the sequencing of other
individuals, had 23%–76% of wild-type activity (table
5).
However, cytochrome c is a soluble protein and is not
a physiologic substrate for normal, membrane-bound
POR (Lu et al. 1969). Therefore, we supplemented this
classic assay with direct assays of the capacity of POR
mutants to support catalysis by a cytochrome P450 en-
zyme. We previously reported assays of POR activity
that were based on its ability to support catalysis by
P450c17 with the use of doubly transformed yeast
(Flu¨ck et al. 2004). In this system, a yeast strain lacking
the gene for yeast POR was transiently transfected with
vectors expressing human P450c17 and POR (Auchus
et al. 1998). This system was originally developed to
assay P450c17 activities: the transfected human POR
was abundant and not limiting, and the amount of
P450c17 was measured by difference spectra, yielding
reproducible measures of P450c17 enzymology (Auchus
et al. 1998; Arlt et al. 2001), but the ratio of P450c17
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Figure 3 Model of human POR, showing the location of the mutants. The model is based on the X-ray crystal structure of rat POR and
was created using the programs DeepView and POVRAY (see the Persistence of Vision Raytracer Web site). The a-carbon backbone is shown
as a narrow ribbon, permitting visualization of buried residues. The missense residues identified by sequencing are depicted by charged packed
sphere images. Mutations retaining 150% of activity are shown in green, those retaining 25%–50% are shown in blue, and those retaining
!25% are shown in red. Ball-and-stick models are used to represent the FMN (yellow), FAD (yellow) and NADPH (cyan) moieties.
to POR could not be measured or chosen precisely. How-
ever, when POR is limiting, the 17,20 lyase activity of
P450c17 is sensitive to changes in the molar ratio of POR
to P450c17 (Yanagibashi and Hall 1986; Lin et al.
1993). Therefore, we have developed a modification of
this assay using microsomes containing human P450c17
expressed in yeast, as before, combined with a mem-
brane fraction containing human N-27 POR expressed
in E. coli (fig. 1). Each component is prepared and as-
sayed separately before mixing, so the P450c17:POR
ratio can be set, improving reproducibility and consis-
tency. As the 17,20 lyase activity of P450c17 is facilitated
by the allosteric action of cytochrome b5 (Auchus et al.
1998), we also prepared cytochrome b5 in bacteria, to
add in support of the lyase reactions (fig. 1). Adding
exogenous phosphatidylcholine fostered association of
the yeast and bacterial membranes, permitting associa-
tion of the catalytic components. In this system, POR
remains intimately associated with the endoplasmic re-
ticulum and, thus, has a physiologically relevant mem-
brane insertion. As defective androgen synthesis is a hall-
mark of the patients with POR deficiency and as the
17,20 lyase activity of human P450c17 is exquisitely
sensitive to the topology of its interactions with POR
(Geller et al. 1997; Auchus and Miller 1999; Geller et
al. 1999), we assayed the capacity of the POR mutants
to support the 17a-hydroxylase and 17,20 lyase activ-
ities of human P450c17.
Table 6 shows the Km, Vmax, and Vmax/Km for the 17a-
hydroxylase and 17,20 lyase activities of P450c17 when
catalysis is supported by either wild-type POR or each
of the missense mutants. We previously measured these
values for the A287P, R457H, V492E, C569Y, and
V608F mutants (Flu¨ck et al. 2004). Those prior data are
in excellent agreement with the data in table 6, except
for C569Y, which has lower activity in the present study.
The polymorphic A115V, P228L, R316W, G413S,
A503V, and G504R variants retained 41%–141% of
wild-type activity. The V608F mutant, which had 3%–
8% of wild-type activity in the cytochrome c assays, had
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Table 5
Kinetics of POR Variants Using Cytochrome c as Substrate
POR
VARIANT
VALUE OF VARIABLE  SD FOR
Cytochrome c NADPH
Km Vmax
Vmax/Km (% of Wild
Type) Kcat Km Vmax
Vmax/Km (% of Wild
Type) Kcat
Wild type 1.4  .3 91.2  5.1 65.1 (100) 388 .22  .05 68.4  2.9 310 (100) 292
A115V 2.0  .4 82.5  4.3 41.2 (63) 350 .29  .04 37.2  5.9 128 (41) 158
T142A 1.6  .2 51.3  6.3 32.1 (49) 218 .23  .03 41.7  4.6 161 (52) 178
Q153R 3.7  .4 21.4  5.7 5.7 (9) 90 1.2  .09 43.2  3.1 36 (11) 184
Y181D 150 … … … 150 … … …
P228L 1.4  .3 69.2  5.2 49.4 (75) 294 .24  .06 53.7  3.8 224 (72) 229
M263V 1.9  .2 94.5  3.7 49.7 (76) 402 .39  .07 69.1  2.4 177 (57) 294
A287P 5.9  .8 37.3  6.4 6.3 (9) 158 .71  .10 35.1  4.3 49 (16) 150
R316W 1.9  .4 75.9  8.3 39.9 (61) 322 .29  .07 69.3  9.7 238 (77) 294
G413S 1.3  .2 64.5  7.9 49.6 (76) 274 .20  .05 61.7  2.1 309 (100) 262
R457H 17.2  2.5 7.5  2.1 .43 (.7) 32 150 … … …
Y459H 22.9  6.6 6.1  .7 .26 (.4) 26 150 … … …
V492E 29.7  5.1 6.8  1.1 .22 (.3) 28 150 … … …
A503V 1.8  .2 81.3  6.6 45.2 (69) 344 .21  .06 55.7  1.9 265 (86) 238
G504R 2.1  .2 72.9  4.1 34.7 (53) 312 .35  .06 51.2  3.9 146 (47) 218
G539R 6.3  1.2 37.8  6.7 6.0 (9) 160 18.3  2.1 9.3  1.2 .5 (.2) 40
L565P 2.8  .6 26.2  3.2 9.3 (14) 112 5.3  1.6 23.8  2.3 4.5 (1.4) 102
C569Y 5.8  .2 24.3  2.7 4.1 (6) 104 1.8  .43 12.1  .7 7 (2) 52
V608F 5.2  1.3 26.3  5.2 5.1 (8) 112 3.3  .7 32.7  .6 10 (3) 140
R616X 150 … … … 150 … … …
V631I 1.6  .4 77.3  8.6 48.3 (74) 328 .47  .06 32.8  5.3 70 (23) 140
F646del 3.9  .7 90.7  5.7 23.3 (36) 384 .21  .13 61.2  8.5 291 (94) 260
NOTE.—Km values are in mM (cytochrome c or NADPH); Vmax values are in nmol of cytochrome c reduced/mg POR protein/min. Kcat values
were calculated on the basis of the molar content of POR, and, hence, the values are in min1. POR content of each membrane preparation
was measured, and all samples were normalized against wild-type POR.
57%–80% of wild-type activity in the P450c17 assays.
Other, lesser, differences can be seen by comparing tables
5 and 6.
Careful comparison of the enzymatic data with the
clinical data show that the P450c17 assays provide a
much better correlation between genotype and pheno-
type. Patient 1 was a compound heterozygote for a null
(frameshift) mutation and the novel missense mutation
G539R. This mutant retained 46% of the 17a-hydroxy-
lase activity but only 8% of the 17,20 lyase activity.
Consistent with this, the patient was able to synthesize
cortisol adequately (17a-hydroxylase activity) but had
poor production of sex steroids (17,20 lyase activity).
Patients 2 and 3 were compound heterozygotes, each
carrying the previously described A287P mutation on
one allele but carrying very different mutations on the
other allele. Patient 2 carried F646del, which retained
normal hydroxylase activity and about half of normal
17,20 lyase activity, whereas patient 3 carried a null
(frameshift) mutation on the second allele. Consistent
with this, the hormonal and anatomic phenotype in pa-
tient 2 was less severe, with no genital ambiguity and
normal cortisol (17a-hydroxylase activity) but with
clear evidence of decreased 17,20 lyase activity (elevated
17OHP, low DHEA, and androstenedione). By contrast,
patient 3 had moderately severe genital ambiguity, early
evidence of disordered steroidogenesis, and a more se-
vere skeletal phenotype. A close correlation between as-
says of the 17,20 lyase activity of P450c17 and the gen-
ital phenotype is to be expected, as 17,20 lyase activity
is required for the production of all sex steroids and
because the 17,20 lyase activity is much more sensitive
than the 17a-hydroxylase activity of P450c17 to minor
disturbances in the interactions between P450c17 and
POR (Geller et al. 1997, 1999; Auchus and Miller 1999).
Discussion
Assessment of POR Activity
In the present study, we assayed POR activity both by
the conventional cytochrome c assays (reduction of cy-
tochrome c and oxidation of NADPH) and by a direct
measure of POR-supported catalysis by a microsomal
cytochrome P450 enzyme. For this purpose, we used
steroidogenic P450c17, as its 17,20 lyase activity is very
sensitive to the amount of POR available (Yanagibashi
and Hall 1986; Lin et al. 1993) and to the qualitative
nature of the interaction between P450c17 and POR
(Zhang et al. 1995; Geller et al. 1997, 1999; Auchus et
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Table 6
Kinetics of P450c17 Activities Supported by POR Variants
POR
VARIANT
VALUE OF VARIABLE  SD FOR
17a-Hydroxylase 17,20 Lyase
Km Vmax
Vmax/Km (% of Wild
Type) Kcat Km Vmax
Vmax/Km (% of Wild
Type) Kcat
Wild type 4.3  .09 .149  .021 .035 (100) .67 .93  .18 .059  .014 .063 (100) .27
A115V 3.5  .05 .097  .013 .028 (80) .43 .71  .11 .032  .006 .045 (71) .14
T142A 5.1  .07 .106  .019 .021 (60) .48 .86  .15 .029  .009 .034 (54) .13
Q153R 3.7  .09 .039  .017 .011 (31) .18 .97  .20 .017  .007 .017 (27) .08
Y181D 150 … … … 150 … … …
P228L 3.7  .06 .131  .013 .035 (100) .59 1.54  .21 .041  .005 .026 (41) .18
M263V 7.2  1.7 .025  .011 .003 (9) .11 1.17  .13 .009  .003 .008 (13) .04
A287P 3.5  1.0 .049  .010 .014 (40) .22 1.34  .09 .018  .002 .013 (21) .08
R316W 3.1  .04 .104  .017 .033 (94) .47 .87  .18 .078  .003 .089 (141) .35
G413S 5.9  1.1 .172  .015 .029 (83) .77 1.28  .15 .089  .011 .069 (110) .40
R457H 5.1  1.2 .008  .003 .001 (3) .04 … … … …
Y459H 6.5  1.1 .027  .009 .004 (11) .12 … … … …
V492E 7.7  1.5 .011  .004 .001 (3) .05 … … … …
A503V 5.5  .03 .110  .018 .021 (60) .50 1.04  .09 .037  .006 .035 (56) .17
G504R 3.9  .07 .124  .020 .032 (91) .56 .85  .12 .056  .009 .065 (103) .25
G539R 4.5  1.0 .073  .006 .016 (46) .33 1.95  .27 .009  .002 .005 (8) .04
L565P 5.9  .65 .067  .008 .011 (32) .30 1.39  .16 .017  .005 .0120 (19) .08
C569Y 9.3  1.9 .094  .009 .010 (28) .42 1.22  .15 .010  .012 .008 (13) .05
V608F 3.5  .04 .099  .014 .028 (80) .45 1.03  .17 .037  .012 .036 (57) .17
R616X 4.7  .07 .008  .003 .002 (6) .04 … … … …
V631I 4.3  .06 .077  .008 .018 (51) .34 1.32  .22 .033  .009 .025 (40) .15
F646del 3.5  .07 .118  .011 .034 (97) .53 1.77  .27 .051  .006 .029 (46) .23
NOTE.—Km values are in mM progesterone for 17a-hydroxylase and mM 17OH-pregnenolone for 17,20 lyase. Vmax values are in pmol/mg
P450c17/min. Kcat values were calculated on the basis of the molar content of P450c17, and, hence, the values are in min
1. POR content
of each membrane preparation was measured, and all samples were normalized against wild-type POR.
al. 1998; Auchus and Miller 1999; Pandey et al. 2003).
Our previous studies of POR mutations (Flu¨ck et al.
2004) used a yeast system in which endogenous yeast
POR is absent and human P450c17 and human POR
are expressed in yeast from transiently transfected plas-
mids (Auchus et al. 1998). This system works well, but
it does not permit direct assessment of the amount of
POR present, and each transfection must be tediously
assayed for P450c17 content to calculate meaningful en-
zymatic parameters. In the present study, we modified
this system by using yeast-expressed human P450c17,
combined in vitro with human N-27 POR, prepared
from E. coli. By comparing the enzymatic parameters
(Km and Vmax) obtained for the wild type and for five
different POR missense mutants (A287P, R457H, V492E,
C569Y, and V608F) assessed in the double-transfected
yeast system (Flu¨ck et al. 2004) with those obtained with
the in vitro fused-membrane system (present study), we
see that both systems give similar values for Km and that
the present system yields slightly lower values for Vmax.
Because the present system permits quantitation of all
relevant variables, we consider these values to be a more
reliable approximation of actual POR activity. Never-
theless, actual activity in vivo may vary as a result of
other unknown intracellular factors.
The surface of the electron-donating (FMN) domain
of POR is characterized by acidic residues (Shen and
Kasper 1995; Estabrook et al. 1996; Wang et al. 1997),
whereas the redox-partner-binding site of microsomal
P450 enzymes is typically characterized by basic residues
(Hasemann et al. 1995; Fisher et al. 1996; Geller et al.
1997; Auchus and Miller 1999; Kondo et al. 1999;
Davydov et al. 2000). Thus, electrostatic interactions
between oppositely charged residues are obviously im-
portant in governing the association of POR with a P450
enzyme. Consistent with this, mutation of arginine res-
idues in the POR-binding site of P450c17 selectively
ablates 17,20 lyase activity (Geller et al. 1997, 1999),
and chemical modification of acidic residues in the FMN
site of POR similarly reduces the activity of P450 (Nad-
ler and Strobel 1988, 1991; Shen and Kasper 1995). In
addition, hydrophobic interactions between POR and
P450 also play a role (Strobel et al. 1989). The activities
assessed in different studies are a function of the specific
P450 enzyme used as the readout of the POR activity
and are also a function of the form of POR used. Both
the full-length POR used in our previous studies (Flu¨ck
et al. 2004) and the N-27 human POR used here remain
associated with membranes and are able to support the
reduction of a cytochrome P450. By contrast, when rat
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POR or human POR is rendered wholly soluble by de-
leting 54 N-terminal residues, it can still reduce cyto-
chrome c (which is not a physiological substrate for
POR), but it cannot reduce P450 (Lu et al. 1969; Roman
et al. 2003). Human, rat, and Xenopus PORs have a
long hydrophobic domain following the strongly basic
sequence RKKK (residues 48–51) that resembles a trans-
membrane domain (von Heijne 1984), but this sequence
is not found in Drosophila or yeast POR (fig. 4). Thus,
reliable measurements of POR activity require the use
of a membrane-bound form of POR and a sensitive
P450-based enzymatic readout.
Structure/Function Correlation of POR Mutants
The mutations examined in this study provide reason-
able scanning mutagenesis of POR. Human POR shares
highly conserved binding domains for FMN, FAD, and
NADPH with the PORs of other species (fig. 4), and the
FAD- and NADPH-binding domains are also similar to
the FAD- and NADPH-binding domains of ferredoxin
reductase (Hanukoglu and Gutfinger 1989; Karplus et al.
1991) and nitric oxide synthase (Bredt et al. 1991). By
analogy with the crystallographically determined struc-
ture of rat POR (Wang et al. 1997), residues 143–147
and 173–185 of human POR participate in binding the
isoalloxazine ring of FMN, with the side chain of Y181
stabilizing the interaction with the flavin. Replacing the
rat POR residue Y178 (human Y181) with Asp eliminated
99% of its activity to reduce cytochrome c (Shen et al.
1989), and the corresponding human Y181D mutation
caused ABS (Arlt et al. 2004) and reduced activities to-
ward cytochrome c (table 5) and P450c17 (table 6) to
undetectable levels. The mutation Q153R, which is near
the FMN-binding site, reduced POR activity to ∼30%
(table 5). The highly conserved domain that interacts with
and donates electrons to the cytochrome P450 comprises
residues 194–231, especially residues 178–185 and 210–
214 (DDDGN) (Wang et al. 1997) (fig. 4). We found no
mutations in this domain; the closest mutations were
M263V, which lost ∼90% of activity, and A287P, the
mutation commonly found in patients of European an-
cestry, which lost 60%–80% of activity (table 6). The RY
sequence of residues 316–317 is conserved from yeast to
human POR, suggesting an important function (fig. 4),
yet the nonconservative mutant R316W was found as a
polymorphism in a database and retained normal activity,
as did the conservative polymorphism G413S (table 6).
Thus, the activities of each mutant or polymorphism
must be tested experimentally to determine the degree
of impairment.
The FAD-binding domain (residues 453–495) is
highly conserved, and the sequence RYYSI (457–461) is
invariant among human, rat, Xenopus, Drosophila, and
yeast POR (fig. 4). X-ray crystallography shows that rat
R454 (human R457) forms a hydrogen bond with the
pyrophosphate group of FAD and that rat Y456 (human
Y459) contacts the FAD isoalloxazine ring and hydrogen
bonds with the ribityl 3′-hydroxyl group (Wang et al.
1997; Shen and Kasper 2000). Mutation of each of these
residues caused ABS and ablated virtually all measurable
activity. Similar results were obtained when these mu-
tations were studied in rat POR (Shen and Kasper 1996,
2000; Shen et al. 1999). Residues 491–497, which lie
in helix N, form hydrogen bonds with the FAD pyro-
phosphate (Wang et al. 1997). The mutation V492E is
predicted to disrupt this hydrogen bonding; this muta-
tion causes ABS and is virtually devoid of activity. By
contrast, the conservative change A503V and the non-
conservative change G504R lie in an unstructured loop,
were identified as polymorphisms, and retain 150% ac-
tivity (table 6).
The NADPH-binding domain comprising the car-
boxy-terminus of the protein is highly conserved (fig.
4)—especially the sequence GTGVAP (residues 537–
542), which contains the consensus GXG sequence typ-
ical of NADP-binding proteins (Hanukoglu and Gut-
finger 1989; Scrutton et al. 1990). The mutation G539R
lost 190% activity in the 17,20 lyase assay but retained
46% activity in the 17a-hydroxylase assay, indicating
that the mutant could still bind some NADPH. Consis-
tent with this, the cytochrome c assays showed that the
greatest effect was on NADPH oxidation, for which the
Km value was increased ∼100-fold (table 5). Studies in
which C569 of human POR was alkylated with io-
doacetic acid eliminated activity, implicating a role for
cysteine in the binding of NADPH to human POR
(Haniu et al. 1989), but mutagenesis of the correspond-
ing C566 to S in rat POR suggested that this residue
was not essential, despite a 4.6-fold higher Km value for
NADPH (Shen et al. 1991); alkylation of pig POR did
not change activity (Haniu et al. 1984). The mutation
C569Y in human POR, which we previously found in
a patient with disordered steroidogenesis but without
ABS (Flu¨ck et al. 2004), also had a high Km value for
NADPH (table 5) but retained 13% of 17,20 lyase ac-
tivity and 28% of 17a-hydroxylase activity (table 6).
The C569Y mutation was found as a compound het-
erozygote with V608F (Flu¨ck et al. 2004), which re-
tained 57% of 17,20 lyase activity and 80% of 17a-
hydroxylase activity, thus explaining that individual’s
hormonal profile, which resembled isolated 17,20 lyase
deficiency. The crystallographic data indicated that rat
W677 (human W679) directly participates in interac-
tions with both FMN and NADPH, suggesting that any
carboxy-terminal truncation will have severe conse-
quences. Consistent with this, the premature chain trun-
cation mutant R616X was devoid of activity. The mu-
tations A115V and V631I were detected as hetero-
zygotes only in individuals with normal steroidogenesis,
Figure 4 Amino acid sequence alignment of POR from five species. The protein sequences used are those of human (NCBI accession
number NP_000932.1), rat (NCBI accession number NP_113764.1), Xenopus (NCBI accession number AAH59318.1), yeast (NCBI accession
number NP_596046.1) and Drosophila (NCBI accession number NP_477158.1). Alignments were made with ClustalW and are displayed with
GeneDoc. Residues that are identical in all species (when the residue exists) are highlighted in black, those identical in four of five species are
shown in dark gray, and those identical in three of five species are shown in light gray. Amino acid numbers are shown at the right. Note that
the human POR sequence has a three-residue amino-terminal extension. The functional domains and individual residues discussed in the text
are shown above the human sequence. The location of the truncation used to create the N-27 POR used in the functional assays is shown.
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and hence they may be polymorphisms. A115V is a con-
servative change in a region without apparent function,
and it retained full activity with P450c17 (table 6). Al-
though the conservative mutant V631I lies in a highly
conserved segment of the NADPH-binding domain, it
retained normal activity in the cytochrome c assays (ta-
ble 5) and 40%–50% of activity in the P450c17 assays.
Finally, the in-frame deletion of F646, a residue for
which the crystal structure of rat POR does not ascribe
a specific function, had no effect on 17a-hydroxylase
activity but caused a 54% reduction in 17,20 lyase ac-
tivity. As POR must interact with all 50 human micro-
somal P450 enzymes and as the stereochemistry of those
interactions with different P450 enzymes will vary with
the geometry of the redox-partner-binding site of P450,
it is clear that no assay that is based on a single P450
enzyme will reliably forecast all the consequences of a
specific POR mutant.
Nosology of ABS and POR Deficiency
ABS was initially described as a skeletal malformation
syndrome (Antley and Bixler 1975; DeLozier et al. 1980;
Hassell and Butler 1994); descriptions of genital am-
biguity were added later, as a finding described in about
half of these patients (Crisponi et al. 1997). In contrast
to the autosomal dominant craniosynostosis syndromes
caused by FGFR mutations, reports of ABS in siblings
and in children of consanguineous parents have sug-
gested autosomal recessive inheritance (Reardon et al.
2000). The finding of mutations in receptors for fibro-
blast growth factors, especially FGFR2, in other cran-
iosynostosis syndromes led to the successful search for
FGFR2 mutations in some patients with ABS. These
eponymic syndromes resulting from FGFR2 mutations
may be regarded as presenting variants of a single dis-
ease, as single genotypes often give somewhat varied
phenotypes. Reardon et al. (2000) called attention to
ambiguous genitalia and/or disordered sterol metabo-
lism as the major feature that appeared to distinguish
patients with ABS resulting from FGFR2 mutations from
patients with ABS who lacked FGFR2 mutations. We
recently reported that three such patients, plus another
patient without ABS, carried autosomal recessive mu-
tations in POR, and we provided biochemical and en-
zymologic support for this observation (Flu¨ck et al.
2004). We have now confirmed and expanded that orig-
inal study by sequencing POR in 32 patients, including
12 of the 16 patients studied by Reardon et al. (2000).
Reardon et al. (2000) had suggested that ABS with ab-
normal genitalia was digenic, resulting from mutations
in an FGFR2 gene plus a mutation elsewhere. Although
we failed to find mutations in 3 of the 32 patients, we
found complete genetic segregation of POR and FGFR
mutations in patients with the ABS phenotype. Thus,
digenic inheritance appears to be most unlikely, but it
cannot be completely excluded, as not all FGFR exons
were sequenced.
Patients with ABS with disordered steroidogenesis
have been born to mothers who became virilized during
gestation and, hence, were thought to have luteomas of
pregnancy (Roth et al. 2000; Warmann et al. 2000); it
is more likely that these cases reflect feto-placental hy-
perandrogenism resulting from decreased activity of
POR-dependent aromatase (P450aro), which converts
androgens to estrogens, as described in our initial study
(Flu¨ck et al. 2004). Alternatively, it has been suggested
that increased androgen synthesis through an alternative
“backdoor” pathway (Auchus 2004) may result in the
virilization of mothers carrying a POR-deficient fetus
(Arlt et al. 2004), but definitive data are lacking. It is
noteworthy that, aside from the genital ambiguity, no
dysmorphologic feature distinguishes ABS secondary to
FGFR2 mutations from ABS secondary to POR muta-
tions; thus, this distinction requires careful hormonal
evaluation of adrenal steroidogenesis.
Thus, we propose that the term “ABS” be reserved
for those patients with the skeletal dysmorphologic find-
ings initially reported by Antley and Bixler (1975) but
who have normal genitalia and normal steroidogenesis,
and that patients with the skeletal dysmorphologic phe-
notype plus evidence of disordered steroidogenesis be
referred to as having “POR deficiency.” It is clinically
important to view patients with POR mutations as hav-
ing a disease that is distinctly different from the disease
caused by FGFR mutations. Not only are the genes and
patterns of inheritance different (dominant FGFR mu-
tations vs. recessive POR mutations), but the patients
are also vulnerable to different risk factors and require
different management and different teams of physicians.
Several of the patients with POR mutations died un-
expectedly without clear explanation, and Reardon et
al. (2000) noted that several patients required steroid
hormone supplementation. Now that the steroidogenic
defect is understood, it is apparent that patients with
POR mutations may be at risk for adrenal insufficiency
and Addisonian crisis, especially at times of severe febrile
illness or major surgery. Thus, any patient thought to
have ABS should be evaluated by a pediatric endocri-
nologist for the ability to mount an adequate cortisol
response to stress, as well as for the adrenal and gonadal
pattern of synthesis of C21 and C19 steroids.
The mechanism(s) by which POR deficiency causes a
skeletal disorder resembling ABS remains unclear. Sub-
stantial speculation has centered on cholesterol, as some
disorders of cholesterol biosynthesis include disorders of
skeletal development (Herman 2003). Cholesterol bio-
synthesis requires two POR-dependent enzymes: squalene
epoxidase, a non-P450 enzyme (Ono and Bloch 1975),
and lanosterol demethylase (CYP51). Furthermore, cho-
746 Am. J. Hum. Genet. 76:729–749, 2005
lesterol is required for C-terminal modification of hedge-
hog proteins, which play multiple roles in morphogenesis
(Mann and Beachy 2004). Clinical reports have associated
ABS with maternal ingestion of fluconazole, an antifungal
agent that acts by preferentially inhibiting yeast CYP51
(Pursley et al. 1996; Aleck and Bartley 1997). Lympho-
blastoid cells from a patient having ABS and ambiguous
genitalia accumulated lanosterol and dihydrolanosterol,
consistent with a lesion in CYP51, but the CYP51 gene
was normal (Kelley et al. 2002). We subsequently found
that this individual was homozygous for the POR mu-
tation A287P (Flu¨ck et al. 2004). Although fluconazole
should not inhibit human CYP51, the absence of POR-
dependent hepatic enzymes that normally metabolize flu-
conazole might permit fetal concentrations to rise sub-
stantially. However, liver-specific knockout of Por yields
morphologically normal mice (Henderson et al. 2003; Wu
et al. 2003), whereas the global Por-knockout mouse is
embryonic lethal (Shen et al. 2002; Otto et al. 2003).
Thus, the absence of a hepatic P450 activity appears to
be unrelated to the dysmorphology of POR deficiency in
mouse. Similarly, Otto et al. (2003) suggested that the
phenotype might be associated with decreased activity of
CYP26, which degrades retinoids; decreasing the retinoic
acid in the diets of pregnant mice carrying Por-knockout
fetuses partially ameliorated the phenotype. However, as
CYP26 is also a hepatic enzyme, the answer would appear
to lie elsewhere. We speculate that the dysmorphology in
POR deficiency is associated with a decrease in one of
the numerous extrahepatic enzymes that require electron
transfer from POR.
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